Rime Bioinformatics

Executive Summary

Rime Bioinformatics aims to democratize high-performance bioinformatics for medical, agronomic, and veterinary research, focusing on developing alternatives to antibiotics. Founded in 2018 and based in Paris, the company addresses the bottleneck of in silico analysis of DNA/RNA sequencing data, which often hampers research progress. By providing accessible computational tools, Rime enables researchers to accelerate their workflows and reduce reliance on time-consuming in vivo and in vitro methods. The company's services span multiple sectors, reflecting a diversified approach to tackling antimicrobial resistance. Despite limited public information, Rime's niche in bioinformatics for antibiotic alternatives positions it well within the growing One Health and precision medicine markets. With no disclosed funding or valuation, the company may be bootstrapped or in early stages, but its focus on high-demand areas suggests potential for partnerships and growth. Key upcoming catalysts could include product launches, strategic collaborations, or funding milestones that validate its platform and expand its user base. Overall, Rime Bioinformatics represents a promising but early-stage player in the bioinformatics space.

Upcoming Catalysts (preview)

• Q3 2026Launch of AI-powered bioinformatics platform for antibiotic discovery60% success
• Q3 2026Strategic partnership with major pharmaceutical or agricultural company40% success
• Q3 2026Series A funding round to scale operations50% success